MAIA appoints HCC specialists to SAB; Phase 2 trial enrollment expected by year-end 2025

MAIA Biotechnology, Inc.

Appointed Drs. Claudia Fulgenzi and David J. Pinato to SAB; both are HCC clinician-scientists.
Planning Phase 2 trial of ateganosine (THIO) plus checkpoint inhibitor in hepatocellular carcinoma (HCC).
Expects to begin enrolling HCC trial patients by end of 2025 upon obtaining regulatory approvals.
FDA granted Orphan Drug Designation for ateganosine in HCC in 2022, potentially 7-year market exclusivity.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.